Kornimate/medical-research-clean huggingface dataset:
effect of periodontal treatment on the biomechanical properties of the periodontium.

Conditions: Periodontal Diseases

Summary: investigation of the biomechanical properties of the periodontal tissues in patients with periodontal disease. non-surgical periodontal therapy will be assessed between baseline and 30 post-op by general clinical measurements (kt, ppd, cal, bop) as well as by biomechanical analysis and compared.

the study is designed as a prospective single center comparative clinical trial to investigate the biomechanical properties of the periodontal tissues in 30 patients with periodontal disease. success of non-surgical periodontal therapy between baseline and 30 post-op will be assessed by general clinical measurements (kt, pd, cal, bop) as well as by biomechanical analysis. besides assessment for regular treatment effectiveness, safety parameter such as wound healing and adverse events will be assessed. additionally 10 periodontally healthy persons without local inflammation and bone loss shall be monitored and used a control group for reference to the test teeth.

Eligibility criteria:
inclusion criteria: * moderate/advanced/severe periodontitis * intact anterior dentition upper yaw. * expected performance of adequate oral hygiene * subjects must have voluntarily signed the informed consent form before any study related procedures * males and females with at least 18 years of age * subjects must be committed to the study and the required follow-up visits * subject must be judged in good general health as assessed by the investigator at time of non-surgical therapy exclusion criteria: * any contraindications for subgingival instrumentation * uncontrolled diabetes or other uncontrolled systemic diseases * disorders or treatments that compromise wound healing * medical conditions requiring chronic high dose steroid therapy * bone metabolic diseases * radiation or other immuno-oppressive therapy * chronic anti-inflammatory treatment (≥3 times per week) within 4 weeks prior to treatment * presence of oral lesions (such as ulceration, malignancy) * mucosal diseases (e.g., lichen planus, mouth ulcer) * history of malignant disease in the oral cavity or previous radiotherapy to the head or neck * treatment with an investigational drug or device within the 30 day period immediately prior to therapy on study day 0 * female subjects who are nursing, pregnant, or plan to become pregnant * antibiotic treatment

Keywords: biomechanics non-surgical periodontal treatment
an objective evaluation of postoperative positioning in macular hole surgery

Conditions: Macular Hole

Summary: the macular hole formation takes place in the centre of the retina. a closure of the macular hole is believed to take place if the central retinal area is kept dry in the postoperative period. therefore the eye is filled with a gas mix and the patients are urged to avoid the supine position in the first postoperative days. the investigators use the "tennis ball technique" where a tennis ball is fastened in the back of the night shirt in order to help patients compliance in avoiding the supine sleeping position. the investigators have developed a positioning measuring device which can measure the extent of supine positioning time. patients are to sleep two nights with the positioning measuring device, one night with a tennis ball in the back of the night shirt and one night without. hereby the investigators search new knowledge concerning patients compliance and verification of the "tennis ball technique".


Eligibility criteria:
inclusion criteria: * pars plana vitrectomy for macular hole, vitreomacular traction or epiretinal membrane where intra ocular gas tamponade is used. * informed consent exclusion criteria: * age less than 18 years

Keywords: macular hole vitrectomy gas tamponade vitreomacular traction in danger of macular hole formation epiretinal membrane in danger of macular hole formation
does ultrasound-guided suprascapular nerve block provide additional benefit over traditional rehabilitation program for patients with chronic shoulder pain

Conditions: Suprascapular Nerve Block

Summary: this study was conducted to compare the efficacy of hydrodilatation with hyaluronic acid under ultrasonographic guidance plus physical therapy (pt) with that of pt alone for treating adhesive capsulitis


Eligibility criteria:
inclusion criteria: 1. chronic shoulder pain with duration of complaints more than 3 months 2. diagnosis of frozen shoulder or rotator cuff disorder exclusion criteria: 1. other conditions involving the shoulder ( rheumatoid arthritis, hill-sachs lesions,osteoporosis, or malignancies in the shoulder region); 2. neurologic deficits affecting shoulder function in normal daily activities; 3. shoulder pain caused by cervical radiculopathy 4. a history of drug allergy to xylocaine 5. pregnancy or lactation; 6. received injection into the affected shoulder during the preceding 3 months

Keywords: suprascapular nerve block
sexual dysfunction and hypotestosteronemia in patients with obstructive sleep apnea syndrome

Conditions: Sleep Apnea, Obstructive; Sleep Apnea; Hypotestosteronism

Summary: obstructive sleep apnea syndrome (osas)is a common disease and is suspected to be associated with sexual dysfunction. our purpose is to sudy the effect of cpap (continuous positive airway pressure) treatment on patients' sexual dysfunction by measuring testosterone levels before and after cpap treatments.

obstructive sleep apnea syndrome(osas) is a highly prevalent disease in the population, affecting at least 4% of males and to a lesser extent females, yet it is currently under diagnosed. osas is associated with various disorders including cardiovascular disease, insulin resistance, diabetes mellitus, fatigue and erectile dysfunction. currently the standard treatment for osas is continuous positive airway pressure(cpap). low testosterone levels are present in some patients with osas leading to erectile dysfunction. however, the true prevalence of low testosterone levels and its correlation with sexual health is poorly understood and undefined. prior data suggest treating these patients with cpap therapy, usually increases testosterone levels, but unclear if this makes any meaningful difference in patient outcome, that is improvement in libido and sexual function. there are several postulations to the pathophysiology of low testosterone levels in patients with osas. crp(c-reactive protein), a strong marker of inflammation was shown to be elevated in patients with osas. the association between elevated crp and low testosterone level would support the notion that inflammation plays a primary role in sexual dysfunction in patients with osas. the objective of this study is to identify correlation between low free testosterone levels, sexual dysfunction and obstructive sleep apnea before and after treatment with cpap. evaluate the role of crp and inflammation secondary to osas in the pathogenesis of sexual dysfunction.

Eligibility criteria:
inclusion criteria: * adult males ages 18-70 with newly diagnosed osas documented by all-night polysomnography (psg) exclusion criteria: * currently on testosterone replacement therapy * prior known cause of erectile dysfunction * patients with prior treatment of erectile dysfunction * co-morbid conditions like diabetes, hypertension, as well as patient medications, will be recorded, and will not be part of the exclusion criteria

Keywords: sleep apnea syndrome sleep apnea cpap low testosterone sexual dysfunction
safety and efficacy study of a food supplement for pregnant and lactating women

Conditions: Anaemia

Summary: the purpose of this study is to determine whether a food supplement consisting of vitamins, minerals and fish oil taken during and after pregnancy can decrease the need for additional iron supplementation due to anemia during pregnancy, and optimize levels of nutritional markers such as vitamin d and docosahexaenoic acid (dha, an omega 3 fatty acid) in maternal blood and breast milk, compared to placebo.

200 healthy, pregnant women will be randomized to receive either active or placebo at their first visit to the pre-natal centres. they will be monitored at regular intervals, blood samples will be taken and they will be asked about compliance and any adverse reactions. approx 8 weeks after delivery, the women will come to the pre-natal centres for a check-up. during this visit, a blood sample will be drawn and a breast milk sample will be collected. the blood samples will be analysed for haemoglobin, serum ferritin, vitamin d and dha. the breast milk samples will be analysed for vitamin d and dha.

Eligibility criteria:
inclusion criteria: * healthy pregnant women aged 18-40 years with a body mass index (bmi) above 18.5 and below 35 kg/m2 who visit pre-natal clinics (midwife centres) to register. * nulliparous and multiparous women. * the women must be able to understand verbal and written information in swedish to give an informed consent to participate in the study. exclusion criteria: * women below the age of 18 or above 40 years old. * women with a bmi below 18.5 or above 35 kg/m2. * women with any form of anaemia as diagnosed at the first visit to the prenatal clinic. * women expecting two or more babies. * women who have undergone bariatric surgery. * women on medication with pharmaceuticals that could affect the result of the study, e.g., vitamin k antagonists. * women who are allergic to any of the components of wellnesspack mama, e.g., fish. * women who suffer from drug or alcohol abuse. * women who suffer from known severe eating disorders. * women who suffer from chronic diseases that could affect gastrointestinal absorption and metabolism. * women who want to continue or start using similar food supplements in addition to wellnesspack mama/placebo, unless recommended by a physician or midwife, will be excluded from the study. * upon miscarriage or transfer to prenatal care specialist, the subject is excluded from the study.

Keywords: pregnancy, lactation, food supplement, anaemia
study of pd-1 antibody combined with chemoradiotherapy in oligometastatic esophageal cancer

Conditions: Esophagus Cancer; Chemoradiotherapy; Oligometastatic Disease; Immunotherapy

Summary: chemoradiotherapy（crt） is the main treatment for esophageal cancer patients with recurrent desease，and checkpoint blockade (pd-1) have been shown to be effective in advanced esophageal cancer. therefore, pd-1 combined with chemoradiotherapy （crt）may further improve the efficacy and become a new method for the treatment of esophageal cancer.this study intends to conduct a single-arm, prospective clinical study, aiming to evaluate the safety and efficacy of pd-1 combined with chemoradiotherapy(crt) in patients with oligometastatic esophageal squamous cell carcinoma.


Eligibility criteria:
inclusion criteria: •≥18 years； * esophageal squamous cell carcinomas； * after radical treatment including surgery or definitive chemoradiotherapy * definition of oligometastases：≤3 metastases, including tumor beds and recurrent anastomotic sites；regional lymph node is defined as one metastatic site（ajcc8th, supraclavicular, mediastinal, abdominal）；metastases lesion in liver, lung, bone and brain is no more than 1. * karnofsky performance status(kps)≥ 70； * no immunotherapy were performed after recurrence； * a white-cell count of at least 3500g/l, a hemoglobin concentration of at least 100 g/l, a platelet count of at least 100,000/ll, aspartate aminotransferase and alanine aminotransferase levels of within 1.5 times the upper limit of normal, a serum bilirubin level of 1.5 mg/dl or less, a creatinine level of 1.1 mg/dl or less; * hepatitis virus indicators: normal or hepatitis virus dna titer less than 500 at the same time in an infectious disease hospital, and with the consent of the doctor can be treated； exclusion criteria: * pregnancy, possible pregnancy, or breast-feeding; * psychological, family, social and other factors lead to uninformed consent; * an esophageal mediastinal fistula and/or an esophageal tracheal fistula prior to treatment; * serious complications such as ischemic heart disease, arrhythmias, or other types of heart disease requiring treatment; liver cirrhosis; interstitial pneumonia or pulmonary fibrosis; active gastrointestinal bleeding; mental disorders being treated with antipsychoticagents or requiring treatment; * controlled diabetes mellitus; * a history of autoimmune disease, autoimmune disease (such as colitis, hepatitis, hyperthyroidism, including but not limited to these disease or syndrome) and a history of immune deficiency, including test positive for hiv, or has other acquired, congenital immunodeficiency disease, or have a history of organ transplantation and the history of allogeneic bone marrow transplantation; * a history of interstitial lung disease and a history of non-infectious pneumonia; * active hepatitis b (hbv dna ≥ 2000 iu/ml or 104 copies /ml), hepatitis c ;(positive hcv antibody and hcv-rna above the detection threshold of the assay） * any situation that is unstable or may compromise patient safety and compliance ; * active infections, such as active tuberculosis, are present;
preoperative use of liraglutide additionally to common dietological measures as opposed to dietological measures alone

Conditions: Obesity, Adolescent

Summary: the aim of the study is to investigate the effects of preoperative saxenda (liraglutide). there are two groups, one group receives saxena in addition to dietary measures when first seeking the operation, one group only diet. the investigator is researching how much additional preoperative weight loss is possible with the drug admitted preoperatively.

the aim of the study is to investigate the effects of preoperative saxenda (liraglutide). there are two groups, one group receives saxena in addition to dietary measures, one group only diet. each group will have a waiting period of 6 months until the operation will be done. the investigator wants to elaborate how much additional preoperative weight loss is possible with the drug. the greater the preoperative weight loss, the lower the risk of the operation. after one year, the investigator will also check whether the weight loss has been maintained and whether the preoperative saxenda continues to lose even more weight after the operation. all patients looking for bariatric surgery with health insurance via österreichische gesundheitsklasse and bmi\>35kg/m2 will be asked to take part in this study. patients with previous bariatric surgeries or contraindications against liraglutide will be excluded from this study.

Eligibility criteria:
inclusion criteria: - patients seeking bariatric surgery * bmi \> 35.0 kg/m2 * health insurance via österreichische gesundheitskasse * willingness to be assigned to either of the two groups * willingness to adhere to preoperative dietological measures * follow-up anticipation with blood draws and body weight scans using secca scale * written informed consent exclusion criteria: * patients with previous bariatric surgerys * patients aged below 18 years * patients with bmi \< 35 kg/m2 * patients with psychiatric disorders * patients not willing to adhere to preoperative dietological measures * patients with contraindications against saxenda * patients who have health insurance other than österreichische gesundheitskasse

Keywords: obesity bariatric surgery metabolic surgery liraglutide saxenda weight loss surgery risk reduction excess weight loss
high versus low dose nitroglycerin in acute pulmonary edema

Conditions: Pulmonary Edema

Summary: the goal of this randomized controlled trial is evaluate the out come of: * low dose (\< 100 mic/min )versus * high dose (\> 100 mic/min) of nitroglycerin in management of patients with acute pulmonary edema presented to emergency department of alexandria university hospitals. the main questions it aims to answer is: * time of resolution of high blood pressure, hypoxia, tacchypnea * need for invasive mechanical ventilation, icu admission

this single blind parallel randomized controlled trial will be conducted on (30 patients in each group) presented to alexandria university hospitals with acute pulmonary edema defined as: acute onset of dyspnea \< 6 hrs, tacchypnea ( respiratory rate ≥30 breaths/min), bilaterak crepitations, o2 saturation \< 90% on room air with associted sympathetic surge recognized by presence of tacchycardia, agitationa and blood pressure ≥ 160/90 mmhg all patients included in the study will be allocated randomly using computer software with concealment of randomization in to two groups: * group (a): low dose group nitroglycerin at will be initiated at a rate \<100 mic/min (15) * group (b): high dose group initial dose \> 100 mic /min (15) will be started blood pressure will be measured for both groups every 15 minutes and dose adjusted accordingly, if the blood pressure starts to decrease continue infusion rate. in case of rising or constant blood pressure increase nitroglycerin by 20 mic/min every 15 min till blood pressure starts to decrease. initial, peak rate within the first hour, duration of iv nitroglycerin infusion will be recorded in both groups. initial and maximum dose of loop diuretic will be recorded in both groups. outcome: patients will be followed during ed stay to compare the two groups as regard: * time of resolution of high blood pressure. * resolution of hypoxia. * resolution of tachypnea. * need for invasive mechanical ventilation. * need for icu admission. * length of hospital stay. * incidence of drug side effects as hypotension. * mortality.

Eligibility criteria:
inclusion criteria: * all adult patients (\> 18 years) presented with sympathetic crashing acute pulmonary edema. exclusion criteria: 1 - patients indicated for emergency endotracheal intubation. 2-patients with history of nitroglycerin allergy. 3-preload dependent patients as patients with aortic stenosis. 4-drug interaction with nitroglycerin as sildenafil, ergots. 5-patients indicated for emergency percutaneous intervention.

Keywords: nitroglycein dose pulmonary edema
home-based functional exercise program in patients with patellar femoral syndrome over a 10-week period

Conditions: Patellar Femoral Syndrome

Summary: the purpose of this study is to determine if a 10 week exercise rehabilitation program decreases anterior knee oain (pfps) and improves function in patients with patellofemoral pain syndrome (pfps). individuals (age 18-50) with pfps will be recruited to participate in this study to see if a 10 week exercise program focusing in core and hip strengthening, lower extremity strengthening foot intrinsic strengthening can decrease pain and increase function.

patellofemoral pain syndrome (pfps) is a very prevalent condition that presents in great number to patients in physician's offices and has a high recurrence rate. physical therapy and exercise therapy to strengthen the quadriceps is often prescribed, however recurrence is common. it is hypothesized that pfps patients have core weakness, hip strength abnormalities and neuromuscular control deficits.

Eligibility criteria:
inclusion criteria: * individuals wishing to participate in study voluntarily * subjects diagnosed with patella-femoral syndrome. we will ascertain this by asking a few questions, which will not be recorded as they have not been enrolled in the study yet. * capable of following and completing a 10 week home exercise program exclusion criteria: * individuals with prior knee surgery, tibial plateau fractures, known diagnosis of knee injuries such as meniscus or ligaments tears. * individuals unable to participate, i.e. cognitive deficits, weakness or functional deficits to upper extremities. * individuals unable to tolerate exercise program
study of incidence of respiratory tract aes in patients treated with tyvaso® compared to other fda approved pah therapies

Conditions: Pulmonary Arterial Hypertension

Summary: a surveillance of respiratory tract related adverse events in patients treated with tyvaso®(treprostinil) inhalation solution versus other fda approved therapies

a post marketing surveillance to determine the type and incidence of oro/nasopharyngeal or pulmonary adverse events that may occur in patients treated with commercially available tyvaso®(treprostinil) inhalation solution. a comparison will be made to the type and incidence of events in patients receiving other fda approved therapies for pulmonary arterial hypertension, as a control measure.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of pah, who group i * prescribed and is currently receiving tyvaso and/or other fda-approved therapy for the treatment of pah * willing and able to provide written informed consent exclusion criteria: * previous initiation and permanent discontinuation of tyvaso * participation in an investigational clinical drug or device trial within 30 days of enrollment * current or past diagnosis of lung neoplasm * active gastrointestinal or pulmonary bleed at enrollment * planned surgical intervention for treatment of pah e.g., atrial septostomy or transplant

Keywords: pulmonary arterial hypertension pah treprostinil sodium tyvaso inhalation ventavis iloprost prostacyclin epoprostenol sodium flolan veletri subcutaneous and intravenous prostacyclin analogue remodulin oral era bosentan tracleer ambrisentan letairis oral pde5 inhibitors sildenafil revatio tadalafil adcirca opsumit macitentan adempas riociguat orenitram oral treprostinil
evaluation of the effect induced by repeated administration of topical local anaesthetic (emla) on itch

Conditions: Lidocaine; Itch

Summary: in this experiment, the investigators would like to study if the repeated application of local cuaneous anaesthetic emla cream will reduce itch induced by small needles from the plant mucuna pruriens (also known as cowhage) and histamine (an itch proving substance formed in the body).


Eligibility criteria:
inclusion criteria: * healthy men and women * 18-60 years * speak and understand english exclusion criteria: * pregnancy or lactation * drug addiction defined as any use of cannabis, opioids or other drugs * previous or current neurologic, musculoskeletal or mental illnesses * lack of ability to cooperate * current use of medications that may affect the trial * skin diseases * consumption of alcohol or painkillers 24 hours before the study days and between these * acute or chronic pain * participation in other trials within 1 week of study entry (4 weeks in the case of pharmaceutical trials) * known history of anaphylactic shock, or local allergy (contact dermatitis) to lidocaine, prilocaine or other local anaesthetics of the amide type.